Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Dupixent TM
Active ingredients: dupilumab
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).,Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Shake
- Store in Original Container
- Protect from direct sunlight
- Refrigerate
- Do not Freeze
- Protect from Light
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).,Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Shake
- Store in Original Container
- Protect from direct sunlight
- Refrigerate
- Do not Freeze
- Protect from Light
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).,Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Shake
- Store in Original Container
- Protect from direct sunlight
- Refrigerate
- Do not Freeze
- Protect from Light
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).,Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Shake
- Store in Original Container
- Protect from direct sunlight
- Refrigerate
- Do not Freeze
- Protect from Light
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Do not Shake
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Do not Shake
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Do not Shake
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Do not Shake
- Protect from Heat
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Refrigerate
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Refrigerate
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Refrigerate
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Refrigerate
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Do not Freeze
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Do not Freeze
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Do not Freeze
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
What it is used for
Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Do not Freeze
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient dupilumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
Top results
New Asthma Treatment & Medication - Asthma Australia
Read about the latest information on asthma management, treatment, medications and the updated version of the Asthma Australia Handbook. Learn more here.
Read more on Asthma Australia website
Eczema - Australasian Society of Clinical Immunology and Allergy (ASCIA)
Eczema is a chronic health condition that affects the skin, causing redness, dryness itching and sometimes infections. When eczema worsens it is called an eczema flare and usually there is no single factor for an eczema flare. Eczema flares can be triggered by a range of irritants (see Q 8) or for no obvious reason.
Read more on ASCIA – Australasian Society of Clinical Immunology and Allergy website
Top results
